Downstream sample preparation for subsequent quality attribute analysis represents “a significant bottleneck in process development for non-antibody biologics,” wrote Kevin Brower, PhD, global head of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback